AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$BLTE

Chuang Hao-Yuan sold $12.8M of BLTE

Chuang Hao-Yuan (Chief Financial Officer) sold 67,395 shares of BELITE BIO, INC (BLTE) at an average of $189.98 ($180.16–$198.05, $12.80M total) across 19 trades over 2026-09-04 to 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chuang Hao-Yuan
Published Sep 9, 2026, 11:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 12:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BLTE
Bearish
medium confidence
Mentioned
$BLTE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLTEBearishLow
01

Why it matters

The insider sell could be interpreted as a negative signal, but the pre‑arranged nature tempers the impact.

02

Market read

Primary insider sale with material dollar amount; modest trading relevance for BLTE.

03

What to watch

No immediate catalyst; the CFO may be diversifying personal portfolio.

Relevance 6/10Novelty 8/10Timing: post filing today

Background

Form 4 filings disclose insider transactions; a $12.8M sale by the CFO is a primary source event.

Company-level read

Ticker impact

$BLTEBearishMedium confidence
Context

CFO Chuang Hao-Yuan sold 67,395 shares for $12.8M via a 10b5‑1 plan, reducing his stake to 26,038 shares.

Expected impact

Potential downward pressure over the next few trading sessions.

Evidence & confidence

The sale size ($12.8M) is material for a micro‑cap biotech and was executed under a pre‑arranged plan, suggesting a neutral to bearish signal.

Market effects

Sector

May raise concerns for other biotech micro‑caps with insider sales.

Regional

Limited to U.S. OTC biotech segment.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The sale was pre‑arranged under a 10b5‑1 plan, possibly unrelated to company outlook.

Key entities

  • Company
    Belite Bio, Inc.

    Biotech firm listed under ticker BLTE.

  • Executive
    Chuang Hao-Yuan

    Chief Financial Officer of Belite Bio.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BLTE insider trading history →

Related articles

$BLTEHighAI 8/10

Belite Bio Says Nasdaq Approved Move to Higher Listing Tier

Belite Bio (BLTE) announced its approval to move to Nasdaq's Global Select Market, starting Oct. 19. The company expects increased institutional investor attention and improved liquidity. Belite Bio is seeking approval for tinlarebant, its lead treatment for Stargardt disease, with the FDA setting a Feb. 12, 2027, action date.

econotimes.com
$BLTEMed

Belite Bio stock price target maintained at $245 by H.C. Wainwright

H.C. Wainwright maintained a $245 price target for Belite Bio (BLTE) after regulatory submissions in three countries. The stock is up 88% over the past year, with analysts showing strong optimism. Belite Bio submitted applications for tinlarebant, a treatment for Stargardt disease type 1, in Singapore, the UK, and Switzerland. The company aims for a global launch, with a first-mover advantage if approved.

investing.com
$BLTEMedAI 8/10

Belite Bio submits drug applications in Singapore, UK, Switzerland

Belite Bio (BLTE) submitted Marketing Authorization Applications for tinlarebant, a treatment for Stargardt disease type 1, in Singapore, the UK, and Switzerland. The company also filed applications in the US and Japan, with the US application receiving Priority Review. Tinlarebant met its primary endpoint in a Phase 3 trial and has received several regulatory designations.

investing.com